Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

July 8, 2008

Evolence: Will this New "Advanced" Collagen Filler Take Hold?

This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Analysis By:
Adam Schaffner, Plastic and Reconstructive SurgeonAdam Schaffner
Plastic and Reconstructive Surgeon, The Detroit Medical Center
Implications: Evolence is an injectable filler material that is made by an "advanced collagen GLYMATRIX™ Technology."  Collagen has generally fallen out of favor amongst aesthetic physicians due to its short duration of action.  Evolence will have to demonstrate that it is superior to the plethora of other injectable filler materials currently available to gain market share.  To do so will not only require clinical efficacy, it will also require a tremendous marketing effort to penetrate a market where there is no shortage of injectable filler materials from which to choose.

Analysis: The market currently has a variety of injectable filler materials from which to choose.  The leaders are hyaluronic acid-based materials such as Restylane/Perlane (Medicis) and Juvederm Ultra/Juvederm Ultra Plus (Allergan).  Other fillers that are widely used include Radiesse (BioForm) and Scultpra (Dermik/Sanofi-Aventis).  Artefill (Artes Medical) is also used, though not as widely due to many concerns due to its permanence.  Evolence introduces collagen back into the market.  Previously, collagen based products either required allergy testing (e.g., Zyderm/Zyplast) or were relatively short in its duration of effect (e.g., CosmoDerm/CosmoPlast).  If Evolence can demonstrate some superiority over the plethora of products currently available, it may gain some market share.  However, to do so will require a tremendous marketing effort and potential financial incentives as well. 

Other Analyses of the Same Source Article:
And yet, another filler? Is this the Holy Grail?
July 8, 2008, Author: Alan Zaccaria, MD, Plastic Surgeon, Alan Zaccaria, MD, FACS
why are we going backwards
July 3, 2008, Author: GLG Expert Contributor
Canadian Experience with Evolence
July 2, 2008, Author: GLG Expert Contributor
Evolence Approval- what effect will it have on the filler market
July 2, 2008, Author: Sunil Dhawan, MD, Clinical Assistant Professor of Dermatology, Stanford University
Concerns about Evolence being successful.
July 2, 2008, Author: GLG Expert Contributor

Report a Concern

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-29T17:45:16.633